NCT00046800已完成2 期
A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 21
研究概览
简要总结
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Confirmed relapsed ovarian cancer.
- •Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
- •One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
- •At least three weeks since prior chemotherapy and recovery from any related toxicities.
- •At least four weeks since prior radiotherapy and recovery from any related toxicities.
排除标准
- 未提供
研究者
研究点 (21)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung CancerCarcinoma, Small CellSCLCNCT00046787Astellas Pharma Inc47
终止
2 期
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active InflammationCrohn's DiseaseNCT03850509Otsuka Pharmaceutical Development & Commercialization, Inc.3
已完成
3 期
OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube PlacementOtitis Media With EffusionNCT01949142Otonomy, Inc.266
已完成
3 期
OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube PlacementOtitis Media With EffusionNCT01949155Otonomy, Inc.266
终止
2 期
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) PatientsCOVID-19NCT04458298Ashvattha Therapeutics, Inc.28